Abstract | BACKGROUND: PATIENTS AND METHODS: For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m(2), day 1, plus 5-FU 1000 mg/m(2), days 1-5 (CF), either alone or in combination with cetuximab (CET-CF; 400 mg/m(2) initial dose followed by 250 mg/m(2) weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. RESULTS: Sixty-two eligible patients were included, 32 receiving CET-CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% versus 0%) and diarrhea (16% versus 0%). The overall response rate according to RECIST criteria was 19% and 13% and the disease control rate 75% and 57% for the CET-CF and CF arms, respectively. With a median follow-up of 21.5 months, the median progression-free survival was 5.9 and 3.6 months and median overall survival 9.5 and 5.5 months for CET-CF and CF, respectively. No KRAS codon 12/13 tumor mutations were identified in 37 evaluated samples. CONCLUSION:
|
Authors | S Lorenzen, T Schuster, R Porschen, S-E Al-Batran, R Hofheinz, P Thuss-Patience, M Moehler, P Grabowski, D Arnold, T Greten, L Müller, N Röthling, C Peschel, R Langer, F Lordick |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 20
Issue 10
Pg. 1667-73
(Oct 2009)
ISSN: 1569-8041 [Electronic] England |
PMID | 19549707
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Cetuximab
- Cisplatin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, pathology, secondary)
- Cetuximab
- Cisplatin
(administration & dosage, adverse effects)
- Combined Modality Therapy
- Cross-Over Studies
- Diarrhea
(chemically induced)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Esophageal Neoplasms
(drug therapy, pathology, secondary)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Nausea
(chemically induced)
- Neutropenia
(chemically induced)
- Survival Analysis
- Time Factors
- Treatment Outcome
|